13100 13,14-dihydro-15-keto-tetranor Prostaglandin D2
13,14-dihydro-15-keto-tetranor Prostaglandin D2 Workbook Links
Cayman offers a variety of analysis tools to assist you.
Chemical structure definitions are available for many Cayman products. See Chemical Structure Database for details.
|
A common metabolic pathway for several prostaglandins (PGs), including PGD2, involves the reduction of the double bond between C-13 and C-14 and oxidation of the hydroxyl group at C-15, producing 13,14-dihydro-15-keto PGs. The removal of four carbons at the α-terminus and oxidation of the terminal ω-carbon produces the abundant urinary metabolites, including tetranor-PGDM.1
13,14-dihydro-15-keto-tetranor PGD2 is a potential metabolite of PGD2. It would be produced from the known metabolite 13,14-dihydro-15-keto PGD2 (Catalog No. 12610), which is a known agonist for the CRTH2/DP2 receptor.2
|
|
1
Song, W., Wang, M., Ricciotti, E., et al. Tetranor PGDM, an abundant urinary metabolite reflects biosynthesis of prostaglandin D2 in mice and humans. J Biol Chem 283(2) 1179-1188 (2008).
2
Rangachari, P.K., Betti, P. Biological activity of metabolites of PGD2 on canine proximal colon. Am J Physiol 264, G886-G894 (1993).
|
Purchase 13100 13,14-dihydro-15-keto-tetranor Prostaglandin D2
Pricing is for North America only. Other customers should contact a distributor in their region.
This product is also available to buy in bulk quantities.
Please contact our
Sales Department
for a quote or to purchase.
Cayman strives to be a reliable biochemical reagent vendor by providing the best possible products and services.
To ask for assistance with one of our products please contact our Technical Help staff.
Warning This product is not for human or veterinary use.
|
Pricing updated 2010-03-19.
Prices are subject to change without notice.
|
|
|
|
|
